EICHORCondition: Acute Kidney Injury Due to Sepsis · Sponsor: Novartis Pharmaceuticals
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University Of Alabama | Birmingham, Alabama, United States | — |
| UC San Francisco Medical Center | San Francisco, California, United States | — |
| Stanford Healthcare | Stanford, California, United States | — |
| Emory Johns Creek Hospital | Johns Creek, Georgia, United States | — |
| Northwestern Memorial Hospital | Evanston, Illinois, United States | — |
| Univ Of Iowa Hospitals And Clinics | Iowa City, Iowa, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Beth Israel Deaconess Med Center | Boston, Massachusetts, United States | — |
| Lahey Hospital and Medical Center | Burlington, Massachusetts, United States | — |
| Baystate Medical Center | Springfield, Massachusetts, United States | — |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | — |
| Montefiore Medical Center | The Bronx, New York, United States | — |
+ 67 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996835